Gilead Sciences

3 Blockbuster Drug Launches to Watch This Year
3 Blockbuster Drug Launches to Watch This Year
Motley Fool
drug launches
GSK
Cabenuva
HIV
ViiV
Gilead Sciences
Trodelvy
Eli Lilly
Retevmo
cancer
Flag link:
Gilead says Veklury should work against COVID-19 variants
Gilead says Veklury should work against COVID-19 variants
Pharmaforum
Gilead Sciences
Veklury
remdesivir
B.1.1.7 variant
Flag link:
After bagging Yescarta exec as CMO, T-cell biotech NexImmune files for $86M IPO
After bagging Yescarta exec as CMO, T-cell biotech NexImmune files for $86M IPO
Fierce Biotech
NexImmune
Gilead Sciences
Kite Pharma
IPOs
Flag link:
Merck comes up short in last-ditch effort to revive $2.54B patent verdict against Gilead
Merck comes up short in last-ditch effort to revive $2.54B patent verdict against Gilead
Fierce Pharma
Merck
Idenis
Gilead Sciences
patents
Harvoni
Sovaldi
Flag link:
Ex-Gilead execs bag $80M to trial drug licensed from Merck KGaA
Ex-Gilead execs bag $80M to trial drug licensed from Merck KGaA
Fierce Biotech
Vera Therapeutics
Merck KGaA
clinical trials
kidney disease
atacicept
Gilead Sciences
Flag link:
The top 10 largest biopharma M&A deals in 2020
The top 10 largest biopharma M&A deals in 2020
Fierce Pharma
M&A
AstraZeneca
Alexion
Bristol-Myers Squibb
MyoKardia
Gilead Sciences
Forty Seven
Merck
VelosBio
Nestle
Aimmune
Immunomedics
JNJ
Momenta Pharmaceuticals
Sanofi
Principia Biopharma
Bayer
Asklepios BioPharmaeutical
Flag link:
Gilead Updates 2020 Guidance with Post-Holiday COVID-19 Spike
Gilead Updates 2020 Guidance with Post-Holiday COVID-19 Spike
BioSpace
Gilead Sciences
COVID-19
remdesivir
Veklury
Flag link:
Gilead & Vir Announce Collaboration To Find Cure For Hepatitis B Virus
Gilead & Vir Announce Collaboration To Find Cure For Hepatitis B Virus
NASDAQ
Gilead Sciences
Vir Biotechnology
hepatitis B
clinical trials
Flag link:
Oxford BioTherapeutics to research cell therapies for Gilead’s Kite
Oxford BioTherapeutics to research cell therapies for Gilead’s Kite
Pharmaforum
Kite Pharma
Gilead Sciences
Oxford BioTherapeutics
solid tumors
blood cancer
cell therapy
Flag link:
Astrazeneca shows megamergers were still possible in 2020
Astrazeneca shows megamergers were still possible in 2020
EP Vantage
M&A
AstraZeneca
Alexion
Bristol-Myers Squibb
MyoKardia
Bayer
Asklepios
Merck
VelosBio
Gilead Sciences
Forty Seven
Immunomedics
JNJ
Momenta
Flag link:
Pfizer, AbbVie, BMS, Teva, Sanofi, Gilead and others ring in 2021 with nearly 600 price hikes
Pfizer, AbbVie, BMS, Teva, Sanofi, Gilead and others ring in 2021 with nearly 600 price hikes
Fierce Pharma
drug pricing
Pfizer
AbbVie
Teva Pharmaceutical
Sanofi
Gilead Sciences
Flag link:
Could a lymphoma drug work better against COVID-19 than Gilead's remdesivir?
Could a lymphoma drug work better against COVID-19 than Gilead's remdesivir?
Fierce Biotech
China
COVID-19
Gilead Sciences
remdesivir
Folotyn
Acrotech Biopharma
Flag link:
Gilead latest pharma to join 2020 trend donating money and amping efforts to fight health inequality
Gilead latest pharma to join 2020 trend donating money and amping efforts to fight health inequality
Fierce Pharma
Gilead Sciences
racial disparity
Flag link:
Fierce Pharma's top 2020 marketing stories pack pandemic punch to digital, reputation and drug launches
Fierce Pharma's top 2020 marketing stories pack pandemic punch to digital, reputation and drug launches
Fierce Pharma
pharma marketing
drug pricing
COVID-19
pandemic
remdesivir
Gilead Sciences
HIV
PrEP
Pfizer
Flag link:
Where Will Gilead Sciences Be in 1 Year?
Where Will Gilead Sciences Be in 1 Year?
Motley Fool
Gilead Sciences
Veklury
remdesivir
COVID-19
Flag link:
The top 5 pharma M&A deals of 2020
The top 5 pharma M&A deals of 2020
Pharmaforum
M&A
AstraZeneca
Alexion
Gilead Sciences
Immunomedics
Forty Seven
JNJ
Momenta
Sanofi
Principia Biopharma
Flag link:
Gilead downsizes multibillion-dollar deal once at center of CEO's rebuild
Gilead downsizes multibillion-dollar deal once at center of CEO's rebuild
Bizjournals
Gilead Sciences
Galapagos
clinical trials
filgotinib
rheumatoid arthritis
inflammatory bowel disease
Flag link:
Gilead inks a billion-dollar deal for a hepatitis drug
Gilead inks a billion-dollar deal for a hepatitis drug
BioPharma Dive
Gilead Sciences
Myr Pharmaceuticals
hepatitis D
M&A
Flag link:
ASH: Gilead's CAR-T med Yescarta shows promise earlier in lymphoma therapy
ASH: Gilead's CAR-T med Yescarta shows promise earlier in lymphoma therapy
Fierce Pharma
Gilead Sciences
Kite Pharma
Yescarta
diffuse large B-cell lymphoma
clinical trials
Flag link:
WHO's decision to reject remdesivir based on flawed study, health experts say
WHO's decision to reject remdesivir based on flawed study, health experts say
Beckers Hospital Review
WHO
Gilead Sciences
remdesivir
COVID-19
Flag link:

Pages